Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...

Researchers studied the efficacy of hydroxyurea at reducing stroke risk in sickle cell anemia, the most common and severe ...

Mar. 5, 2025 — People who take over-the-counter pain relievers after a concussion may recover faster than those who do not take pain relievers, according to a preliminary ... Compound Harnesses ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

Pregnant women with sickle cell disease are at higher risk of complications and require close monitoring, a nationwide French ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Discover effective strategies to minimize sickle cell pain crises and avoid hospitalizations. Leading hematologists share ...

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of vaso-occlusive crises (VOCs).